AIMC Topic: Lymphoma, Large B-Cell, Diffuse

Clear Filters Showing 1 to 10 of 51 articles

Classification of patients with relapsed/refractory large B-cell lymphoma who do not develop early CRS/NE toxicity using ZUMA clinical trial data.

Journal for immunotherapy of cancer
BACKGROUND: We aimed to develop an actionable and feasible prospective clinical model to estimate toxicity risk to assist chimeric antigen receptor (CAR) T-cell therapy providers with the management of patients with relapsed and/or refractory large B...

Machine learning-based histopathological features of histological slides and clinical characteristics as a novel prognostic indicator in diffuse large B-cell lymphoma.

Pathology, research and practice
OBJECTIVE: This study developed and validated a deep learning model based on clinical and histopathological features for predicting the outcomes of diffuse large B-cell lymphoma (DLBCL).

Identification of M2 macrophage-related genes associated with diffuse large B-cell lymphoma via bioinformatics and machine learning approaches.

Biology direct
M2 macrophages play a crucial role in the initiation and progression of various tumors, including diffuse large B-cell lymphoma (DLBCL). However, the characterization of M2 macrophage-related genes in DLBCL remains incomplete. In this study, we downl...

Machine learning-based identification of cuproptosis-related lncRNA biomarkers in diffuse large B-cell lymphoma.

Cell biology and toxicology
Multiple machine learning techniques were employed to identify key long non-coding RNA (lncRNA) biomarkers associated with cuproptosis in Diffuse Large B-Cell Lymphoma (DLBCL). Data from the TCGA and GEO databases facilitated the identification of 12...

5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)-Artificial Intelligence Enters the CAR (-T) (Chimeric Antigen Receptor-T) in Relapsed/Refractory Large B Cell Lymphoma.

International journal of radiation oncology, biology, physics
PURPOSE: Bridging radiation therapy (BRT) is effective for local control in patients with relapsed or refractory large B cell lymphoma who are undergoing chimeric antigen receptor (CAR) T cell therapy. We hypothesized that adaptive BRT (ABRT), which ...

Plasma Cytokine and Chemokine Profiles Predict Efficacy and Toxicity of Anti-CD19 CAR-T Cell Therapy in Large B-Cell Lymphoma.

Clinical lymphoma, myeloma & leukemia
BACKGROUND: Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment for large B-cell lymphoma (LBCL); however, durable complete responses are achieved in only 30% to 40% of patients. Additionally, CAR-T therapy...

A multi-view prognostic model for diffuse large B-cell lymphoma based on kernel canonical correlation analysis and support vector machine.

BMC cancer
BACKGROUND AND OBJECTIVE: Positron emission tomography/computed tomography (PET/CT) is recommended as the standard imaging modality for diffuse large B-cell lymphoma (DLBCL) staging. However, many studies have neglected the role of patients' prognost...

Identification of ferroptosis-related genes associated with diffuse large B-cell lymphoma via bioinformatics and machine learning approaches.

International journal of biological macromolecules
Ferroptosis has emerged as a critical mechanism in the development and progression of various tumors, particularly diffuse large B-cell lymphoma (DLBCL). However, the thorough characterization of ferroptosis-related genes in DLBCL remains inadequatel...